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ABSTRACT 
Triple-negative breast cancers (TNBCs) lack the signature targets of other breast tumors, such 
as HER2, estrogen receptor, and progesterone receptor.  These aggressive basal-like tumors 
are driven by a complex array of signaling pathways that are activated by multiple driver 
mutations.  Here we report the discovery of 6 (KIN-281), a small molecule that inhibits multiple 
kinases including maternal leucine zipper kinase (MELK) and the non-receptor tyrosine kinase 
bone marrow X-linked (BMX) with single-digit micromolar IC50s.  Several derivatives of 6 were 
synthesized to gain insight into the binding mode of the compound to the ATP binding pocket. 
Compound 6 was tested for its effect on anchorage-dependent and independent growth of 
MDA-MB-231 and MDA-MB-468 breast cancer cells.  The effect of 6 on BMX prompted us to 
evaluate its effect on STAT3 phosphorylation and DNA binding.  The compound’s inhibition of 
cell growth led to measurements of survivin, Bcl-XL, p21WAF1/CIP1, and cyclin A2 levels.  Finally, 
LC3B-II levels were quantified following treatment of cells with 6 to determine whether the 
compound affected autophagy, a process that is known to be activated by STAT3.  Compound 6 
provides a starting point for the development of small molecules with polypharmacology that can 
suppress TNBC growth and metastasis. 
 
 
 
 
 
 
 
 
 
 
 
 
  
INTRODUCTION 
Triple-negative breast cancer (TNBC) has taken on added importance in recent years as it is 
characterized by poor prognosis, aggressive behavior, and a lack of specific targets such as 
ER, HER2, or progesterone receptor.  Although chemotherapy is effective for TNBC patients in 
the adjuvant setting, chemotherapy-resistant TNBC is quickly fatal given its rapid growth and 
lack of targeted therapies.  TNBC accounts for approximately 15% of breast cancer cases in the 
United States.  Despite its lower incidence, TNBC contributes disproportionately to breast 
cancer morbidity and mortality compared to other breast cancer subtypes. This can be attributed 
in part to its intrinsic aggressiveness, but much of the excess mortality is due to the absence of 
effective targeted therapies.  New targets and small molecules to probe these targets are 
needed for the development of effective therapeutic agents for the treatment of TNBC 1. 
 Unlike other subtypes of cancer, hormone therapy or biologics such as trastuzumab 
have little effects on TNBC tumors.  There is currently an intense search for vulnerabilities of 
this breast cancer sub-type that can be exploited for the development of targeted therapeutic 
agents.  To identify new targets that suppress growth and metastasis of TNBC tumors, we 
previously screened a commercial library of small molecules using structure-based molecular 
docking.  The focus was on members of the CaMK superfamily of kinases, which are relatively 
unexplored in cancer.  We identified 1, a small molecule that inhibited CaMKIIδ with single-digit 
micromolar IC50s.  Kinome-wide profiling against 337 kinases confirmed that CaMKIIδ was 
among the top 10 targets of the compound, along with other members of the CaMK family, such 
as the maternal embryonic zipper leucine kinase (MELK), and the non-receptor tyrosine kinase 
bone marrow X-linked (BMX). 
 The inhibition of multiple kinases by 1 prompted us to explore the compound and several 
of its derivatives in TNBC breast cancer cell lines MDA-MB-468 and MDA-MB-231.  We focused 
on 6 (KIN-281).  The compound was tested for activity in a panel of 25 kinases.  We explored 
the effects of the compound on cell viability and colony formation in anchorage-dependent and 
independent assays.  We further explored the effect of compounds on pro-apoptotic survivin 
and Bcl-XL, as well as cell cycle protein cyclin-dependent kinase inhibitor 1 (p21WAF1/CIP1). 
Considering the effect on BMX and Bcl-XL we examined the effects of the compound on signal 
transducer and activator of transcription 3 (STAT3) as well as autophagy, which is activated by 
STAT3. 
MATERIALS AND METHODS 
Cell Culture.  MDA-MB-231 or MDA-MB-468 cells were cultured in Dulbecco's Modified 
Eagle Medium (Cellgro, Manassas, VA) supplemented with 10% FBS, 1% 
penicillin/streptomycin in a 5% CO2 atmosphere at 37°C. 
Cell Viability Assay. MDA-MB-231 (104 cells) were plated overnight in 100 µl in each 
well of 96-well plates, and then treated with 1% DMSO (control) or compounds at the indicated 
concentrations for 3 d. 20 µl of 5 mg/mL MTT (Sigma-Aldrich, St. Louis, Missouri) were added to 
each well, and cells were incubated at 37°C in 5% CO2 for 2 h.  Viable cells were quantified at 
absorbance of 570 and 630 nm (reference background). Glioma cells were seeded into 96-well 
plates and treated with KIN compounds.  After 5 d of incubation, cell growth was determined by 
methylene blue staining.   Each experiment was conducted in triplicate and repeated three 
times.  
Western Blot Analysis. Anti-β-actin was obtained from Santa Cruz Biotechnology (CA, 
USA). Anti-LC3B was obtained from Sigma chemicals Co (St. Louis, MO, USA).  Anti-p21, 
cyclin A2, anti-p53, anti-phospho p53 (Ser15), MDMX, anti-phosphor STAT3 (Tyr705), anti-
STAT3, anti- Bcl-XL, anti-survivin, anti-β-catenin, anti-phospho Akt, anti-E-cadherin, were 
obtained from Cell Signaling Technology (Beverly, MA, USA). Total cell lysates were prepared 
in standard RIPA extraction buffer containing protease and phosphatase inhibitors (Sigma-
Aldrich, St. Louis, Missouri).  Thirty micrograms of protein were separated by 10% SDS-PAGE 
and transferred to nitrocellulose membranes (Amersham, Arlington Heights, IL). The 
membranes were immunoprobed with primary antibodies at 4°C overnight separately, followed 
by secondary antibody IRDye 800-conjugated goat anti-mouse IgG (Rockland, 
Immunochemicals, Gibertsville, PA) or Alexa Fluor 680 goat anti-rabbit IgG (Life Technologies, 
Grand Island, NY) for 1 h at room temperature. Bands were detected using Li-Cor Odyssey 
Imaging System (Li-Cor, Lincoln, NE). 
Soft Agar Assay for Colony Formation. 0.5 mL base layer of 0.5% agar in DMEM 
medium containing 10% fetal bovine serum was placed in 24-well plates and permitted to 
solidify at room temperature. Cells to be tested for colony formation were suspended in the top 
layer (0.5 mL) of 0.3% agar in DMEM medium with 10% fetal bovine serum. The agar was 
permitted to solidify at room temperature. 0.25 mL feeding medium was added on the top layer 
with 1% DMSO (control) or compounds at the indicated concentrations for 10 d at 37°C in a 
humidified incubator in an atmosphere of 5% CO2. The feeding medium was change twice a 
week. Cell colonies were stained with 0.005% Crystal Violet and inspected with a dissecting 
microscope. 
  
Electrophoresis Mobility Shift Assay (EMSA).  STAT3 consensus oligonucleotides 
(Santa Cruz, Dallas, TX) were first labeled with [γ32P]-ATP by using polynucleotide kinase 
(Sigma Aldrich, St. Louis, MO).  A total of 2 µg of nuclear protein was incubated with 32P-labeled 
STAT3 probe in binding buffer (10 mM Tris, 50 mM KCl, 1 mM DTT, pH 7.5, 50 ng/µL Poly 
(dIdC), 50 µM EDTA pH 7.5) for 30 minutes on ice. After incubation, the samples were 
separated on 4% native polyacrylamide gel containing 50 mM Tris, pH 7.5, 0.38 M glycine and 2 
mM EDTA. The gel was transferred to Whatman paper, covered with saran wrap and dried at 80 
°C in vacuum dryer for 1-2 h. 32P-labeled bands were visualized by autoradiography. 
Autophagy Assays. Bafilomycin A1 (Enzo) was added at 100 nM for 4 hours before 
harvest of cells. Cells were lysed in NP40 buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM 
EDTA, 1% NP40) with protease and phosphatase inhibitors. Lysates were centrifuged at 
16,300xg for 15 min at 4°C; supernatants were separated by SDS-PAGE. After transfer to 
PVDF, membranes were blocked in 5% milk/PBS for 1 hr at RT and incubated at 4°C overnight 
with primary anti-LC3B antibody from Novus (cat# NB600-1384) at 1:3,000 in 5% milk/PBS. 
Membranes were washed 3x in PBS-T 0.05% Tween and then incubated for 2 hrs with 
secondary (anti-rabbit HRP, 1:10,000) at RT. Membranes were washed 2x in PBS-T 0.05% 
Tween.  Detection was performed by enhanced chemiluminescence after 2-h incubation with 
HRP-conjugated secondary antibodies (Dako). 
Virtual Screening. The program Glide from Schrödinger (Schrödinger LLC, New York, 
NY, 2010) was used for molecular docking of 6 to the MELK ATP binding pocket.  Glide is a 
robust docking program that has been extensively validated in previous studies.  The structures 
of 6 was prepared using LigPrep in Schrödinger. Compound was protonated at pH 7. The 
structure of MELK (PDB ID: 4CQG, 2.57 Å) was prepared for docking. Grid boxes were 
generated for the three proteins for docking in Glide, with a box size of 21 Å and an inner box of 
14 Å. All other parameters were set to default values. A series of binding poses were generated 
by docking 6 and its derivatives against the ATP binding site of each of the three proteins using 
Glide in standard precision (SP) mode. All other parameters were left to default values.   
General Synthesis Methods.  All chemicals were purchased from either Sigma-Aldrich 
or Acros Organics. Column chromatography was carried out with silica gel G (25-63µm). Mass 
Spectra were measured on an Agilent 6520 Mass Q-TOF instrument. 1H NMR and 13C NMR 
spectra were recorded on BRUKER 500 MHz or 400 MHz spectrometer, using TMS as an 
internal standard and CDCl3 or DMSO-d6 as solvents. Chemical shifts (δ values) and coupling 
constants (J values) are reported in ppm and hertz, respectively. Anhydrous solvent and 
  
reagents were all analytically pure and dried through routine protocols. All compounds that were 
evaluated in biological essays had > 95% purity verified by HPLC. 
 2-methyl-6-nitroquinazolin-4(3H)-one (6a). 2-amino-5-nitro benzoic acid (1.821 g, 10.0 
mmol) was added to acetic anhydride (60 mL). The mixture was stirred at 110oC for 5 h. The 
mixture was evaporated to dryness under reduced pressure. The residue was mixed with 
ammonium hydroxide solution (20-28 % NH3 in H2O, 60 mL) and the mixture was stirred at 55oC 
for 10 h. The suspension was cooled to 5oC, and the precipitate was filtered and washed with 
water. The filter cake was dried under vacuum pressure to give the desired product as a bright 
yellow solid (1.560 g, 76% yield).  1H NMR (500 MHz, DMSO-d6) δ 8.74 (d, J = 2.5 Hz, 1H), 
8.48-8.50 (dd, J = 2.5, 9 Hz, 1H), 7.73 (d, J = 9 Hz, 1H), 2.41 (s, 3H); 13C NMR (125 MHz, 
DMSO-d6) δ 160.9, 158.6, 153.1, 144.3, 128.2, 128.2, 121.8, 120.5; HRMS (ESI) m/z: calcd for 
C9H8N3O3Na [M+Na]+  228.0385, found 228.0372. 
            2, 4, 6-trichlorobenzaldehyde (6b). 1, 3, 5-trichlorobenzene (1.81 g, 10 mmol) was 
dissolved in anhydrous THF (36 mLl) and the mixture was stirred at – 78 °C. n-BuLi (1.6 M in 
Hexane) (6.3 mL, 10 mmol) was slowly added into the solution over 0.5 h under – 78 °C. The 
solution became light yellow color. After all the n-BuLi was added, the mixture was kept at – 78 
°C and stirred for 0.5 h then anhydrous DMF (1.32 mL, 17 mmol) was added into the mixture 
dropwise and the resulting light yellow solution was continuously stirred at – 78 °C for another 
1.5 h. The reaction was quenched with 3 N HCl solution (36 mL) while kept the flask at – 78 °C 
and warmed to ambient temperature to afford a colorless solution. The mixture was extracted 
with ethyl acetate (20 mL x 3) and the organic layer was then washed with saturated NaHCO3 
(aq) and brine, respectively. The organic layer was dried over anhydrous MgSO4 and 
concentrated to afford product 6b as a white needle like solid (1.99 g, 96%). 1H NMR (500 MHz, 
CDCl3) δ 10.43 (s, 1H), 7.42 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 187.7, 139.4, 137.8, 130.0, 
128.8. HRMS (ESI) m/z: calcd for C7H4Cl3O [M+H]+  208.92, found 208.9. 
 6-nitro-2-(2, 4, 6-trichlorostyryl)quinazolin-4(3H)-one (6c). A solution of 6a (205 mg, 1 
mmol) and 6b (210 mg, 1mmol) in acetic acid (3 mL) was refluxed for 30 h. The mixture was 
cooled to room temperature, and the precipitate was filtered and washed with methanol (2 mL x 
3). The filter cake was collected to give the desired product as a yellow solid (329 mg, 83 % 
yield). 1H NMR (500 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.25 (m, 1H), 7.82 (m, 1H), 7.75 (s, 2H), 
7.55 (s, 1H), 6.99 (m, 1H). HRMS (ESI) m/z: calcd for C16H9C13N3O3 [M+H]+ 395.96, found 
396.0. 
 N1,N1-diethyl-N4-(6-nitro-2-(2,4,6-trichlorostyryl)quinazolin-4-yl)pentane-1,4-diamine 
(6d).  A solution of 6c (397 mg, 1.0 mmol) and DIEA (0.4 mL) in POCl3 (10 mL) was refluxed for 
  
3h. The mixture was cooled to room temperature and concentrated to remove the solvent. The 
residue was added ice-water, and adjusted pH to 9-10 with saturated solution of Na2CO3. The 
mixture was extracted with EA (10 mL x 3). The combined organic phases were dried with 
anhydrous Na2SO4, filtered and concentrated. The residue was purified by column 
chromatography (PE/EA= 4:1) to give the desired product as a light brown solid (274 mg, 66 % 
yield). HRMS (ESI) m/z: calcd for C16H8Cl4N3O2 [M+H]+  413.93, found 413.9. 
(E)-N1,N1-diethyl-N2-(6-nitro-2-(2,4,6-trichlorostyryl)quinazolin-4-yl)propane-1,2-diamine 
(6e) Compound 6d (415 mg, 1 mmol) was dissolved in THF (15 mL) and the solution was added 
N1,N1-diethylpentane-1,4-diamine (316 mg, 2.0 mmol). The reaction mixture was stirred at room 
temperature for 3h. The mixture was diluted with EA (60 mL). It was washed with water and 
saturated solution of NH4Cl. Then the organic layer was dried by anhydrous Na2SO4 and the 
solvents were removed at reduced pressure. After purified by flash column chromatography 
(30:1, CHCl3/CH3OH), compounds 6e (301 mg, yield 56%) was got as a golden yellow solid. 1H 
NMR (500 MHz, DMSO-d6) 9.01 (s, 1H), 8.42-8.44 (dd, J = 2.0, 9.0 Hz, 1H), 8.19 (d, J = 16.0 
Hz, 1H), 7.88 (d, J = 6.5 Hz, 1H), 7.83 (d, J = 9.5 Hz, 1H), 7.41 (s, 2H), 7.33 (d, J = 16.0 Hz, 
1H), 4.59-4.60 (m, 1H), 2.81-2.82 (m, 4H), 2.69 (m, 3H), 2.03-2.05 (m, 1H), 1.82 (m, 3H), 1.42 
(d, J = 6.5 Hz, 3H), 1.16 (t, J = 7.0 Hz, 6H); 13C NMR (125 MHz, DMSO-d6) δ 163.2, 159.9, 
154.4, 144.2, 137.1, 135.6, 134.0, 132.4, 132.0, 129.7, 128.9, 126.4, 119.7, 113.7, 52.7, 51.0, 
47.5, 34.1, 22.9, 20.3, 10.4; HRMS (ESI) m/z: calcd for C25H28Cl3N5O2  [M+H]+  536.1381, found 
536.1404. 
 (E)-N4-(5-(diethylamino)pentan-2-yl)-2-(2,4,6-trichlorostyryl)quinazoline-4,6-diamine (6). 
To a solution of 6e (310 mg, 0.58 mmol) in MeOH/H2O (1:1, 22mL) was added ammonium 
chloride (310 mg, 5.8 mmol) and Fe powder (167 mg, 2.99 mmol). The resulting solution was 
reluxed for 4h and monitored (by LCMS) for the conversion to the corresponding aniline. The 
reaction was then filtered and the solvent was removed in vacuo. After cooling to room 
temperature, the mixture was filtered through a pad of Celite which was washed with MeOH and 
the filtrate was concentrated in vacuo. The crude residue was adjusted to pH 7 by saturated 
NaHCO3 solution and extracted with CHCl3. The combined CHCl3 layer was then washed with 
brine, dried over anhydrous MgSO4 and solvent was removed in vacuo. The resulting crude 
residue was purified by flash column chromatography (loaded using DCM/Hexane, 1:5 then 
eluted with CHCl3(NH4OH saturated)/MeOH, 10:1) and dried under high vacuum to afford the 
desired product 6 (205 mg, 70%) as red solid.1H NMR (400 MHz, CDCl3)  δ 8.56 (s, 1H), 8.06-
8.02 (d, J = 16.0 Hz, 1H), 7.69-7.66 (d, J = 8.8 Hz, 1H), 7.46-7.42 (m, 1H), 7.39-7.38 (m, 3H), 
7.13-7.07 (m,1H), 4.62 (m, 1H), 3.08-2.94 (m, 6H), 20.2-1.78 (m, 4H), 1.40-1.39 (d, J = 6.4 Hz, 
  
3H), 1.25-1.22 (t, 6H); 13C NMR (100 MHz, CDCl3): δ 168.9, 157.7, 156.9, 144.9, 143.8, 137.8, 
135.2, 133.0, 132.9, 129.6, 128.6, 128.1, 122.9, 115.4, 103.2, 55.1, 46.5, 46.4, 33.5, 22.0, 20.8, 
9.2. HRMS (ESI) m/z: calcd for C25H31Cl3N5  [M+H]+  506.16, found 506.1. 
(E)-N1,N1-diethyl-N2-(6-nitro-2-(2,4,6-trichlorostyryl)quinazolin-4-yl)propane-1,2-diamine 
(17a). Compound 17a (95 mg, 59.3 %yield) was prepared by the same method as 6e. HRMS 
(ESI) m/z: calcd for C23H25Cl3N5O2 [M+H]+ 508.10, found 508.1. 
(E)-N4-(1-(diethylamino)propan-2-yl)-2-(2,4,6-trichlorostyryl)quinazoline-4,6-diamine (17).  
Compound 17 (35 mg, 28% yield) was prepared by the same method as 6. 1H NMR (400 MHz, 
CDCl3) δ 8.55 (s, 1H), 8.18-8.16 (d, J = 7.6 Hz, 1H), 7.95-7.91 (d, J = 16.4 Hz, 1H), 7.68-7.66 
(d, J = 8.8 Hz, 1H), 7.39 (s , 2H), 7.38-7.34 (d, J = 16.0 Hz, 1H), 7.33-7.32 (m, 1H), 7.13-7.11 
(m, 1H), 5.03 (m, 1H), 3.74-3.68 (m, 1 H), 3.17-3.06 (m, 5 H), 1.52-1.50 (d, J = 6.8 Hz, 3H), 
1.31-1.27 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 168.5, 157.9, 156.2, 145.3, 137.5, 
135.2, 133.1, 132.7, 129.1, 128.7, 127.8, 123.3, 115.9, 104.1, 55.1, 46.6, 42.8, 18.9, 8.5. HRMS 
(ESI) m/z: cacld for C23H27Cl3N5 [M+H]+ 478.13, found 478.1. 
(E)-N1,N1-diethyl-N4-(6-nitro-2-(2,4,6-trichlorostyryl)quinazolin-4-yl)butane-1,4-diamine 
(18a).  Compound 18a (105 mg, 72 % yield) was prepared by the same method as 6e. HRMS 
(ESI) m/z: cacld for C24H27Cl3N5O2 [M+H]+ 522.12, found 522.1. 
(E)-N4-(4-(diethylamino)butyl)-2-(2,4,6-trichlorostyryl)quinazoline-4,6-diamine (18).  
Compound 18 (65 mg, 66 %yield) was prepared by the same method as 6. 1H NMR (400 MHz, 
CDCl3) δ 11.49 (br, 1H), 9.16 (br, 1H), 8.11-8.07 (d, J = 16.0 Hz, 1H), 7.50-7.45 (m, 1H), 7.43-
7.42 (m, 2H), 7.35 (s, 2H), 6.95-6.94 (d, J = 7.6 Hz, 1H), 3.75 (br, 2H), 3.14 (br, 6H), 1.97 (m, 
2H), 1.87 (m, 2H), 1.34 (t, J = 6.8 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 158.6, 152.1, 148.2, 
135.9, 135.2, 134.7, 129.8, 129.6, 129.1, 126.8, 124.0, 120.5, 114.1, 104.5, 51.4, 46.5, 40.9, 
25.0, 21.3, 8.3. HRMS (ESI) m/z: calcd for C24H29Cl3N5 [M+H]+ 492.14, found 492.1. 
(E)-N1,N1-diethyl-N3-(6-nitro-2-(2,4,6-trichlorostyryl)quinazolin-4-yl)butane-1,3-diamine 
(19a).  Compound 19a (85 mg, 62% yield) was prepared by the same method as 6e. HRMS 
(ESI) m/z: calcd for C24H27Cl3N5O2 [M+H]+ 522.12, found 522.1. 
(E)-N4-(4-(diethylamino)butan-2-yl)-2-(2,4,6-trichlorostyryl)quinazoline-4,6-diamine (19).  
Compound 19 (25 mg, 31% yield) was prepared by the same method as 6. 1H NMR (400 MHz, 
CDCl3) δ 8.06-8.02 (d, J = 16.0 Hz, 1H), 7.75-7.69 (m, 2H), 7.46-7.42 (d, J = 16.4 Hz, 1H), 7.38 
(s, 2H), 7.14-7.15 (d, J = 9.2 Hz, 1H), 4.54-5.52 (m, 1H), 3.43-3.37 (m, 1H), 3.18-3.16 (m, 2H), 
3.11-2.98 (m, 4H), 2.45-2.36 (m, 1H), 2.15-2.10 (m, 1H), 1.46-1.45 (d, J = 6.4 Hz, 3H), 1.33 (t, J 
  
= 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 158.4, 155.7, 145.8, 135.6, 135.4, 133.4, 132.3, 
129.3, 128.7, 127.5, 123.3, 115.5, 104.2, 49.6, 45.2, 30.7, 20.9, 8.3. HRMS (ESI) m/z: calcd for 
C24H29Cl3N5 [M+H]+ 492.14, found 492.1. 
3-(2,4,6-trichlorophenyl)propanoic acid (21a).  A mixture of 6b (0.81 g, 3.87 mmol), 2,2-
dimethyl-1,3-dioxane-4,6-dione (0.61 g, 4.26 mmol), triethylamine (780 mg, 7.72 mmol) and 
formic acid (0.87 g, 19.mmol) in DMF (20 mL) was stirred at 100oC for 3h. The mixture was 
cooled to room temperature and water was added (60 mL). The mixture was extracted with EA 
(25 mL x 2). The combined organic layers were washed with water and brine. The solution was 
dried with anhydrous Na2SO4, filtered and concentrated to give the desired product as a white 
solid (0.9 g, 92.4 % yield).  1H NMR (400 MHz, CDCl3) δ 11.56 (br, 1H), 7.32 (s, 2H), 3.26-3.22 
(t, J = 8.4 Hz, 2H), 2.63-2.59 (m, 2H). HRMS (ESI) m/z: calcd for C9H6Cl3O2 [M-H]- 250.95, 
found 250.9. 
6-nitro-2-(2,4,6-trichlorophenethyl)quinazolin-4(3H)-one (21b).  A mixture of 3-(2,4,6-
trichlorophenyl)propanoic acid (0.9 g, 3.6 mmol) in SOCl2 (10 mL) was refluxed for 2h. The 
mixture was concentrated to dryness to give 2-(2,4,6-trichlorophenyl)acetyl chloride (1.0 g, 
crude). To the acyl chloride was added dropwise the solution of 2-amino-5-nitrobenzoic acid 
(0.65 g, 3.6 mmol) in pyridine (15 mL). The mixture was stirred at room temperature for 2 h. LC-
MS showed the reaction was completed. The reaction was concentrated to remove the solvent 
and the residue was added acetic anhydride (20 mL). The mixture was stirred at 110oC for 4 h. 
The mixture was evaporated to dryness under reduced pressure. The residue was mixed with 
ammonium hydroxide solution (20-28 % NH3 in H2O) and the mixture was stirred at 60oC for 2h. 
The suspension was cooled to 5oC, and the precipitate was filtered and washed with water. The 
filter cake was dried under vacuum pressure to give the desired product as a yellow solid (1.13 
g, 79.8 % yield).  1H NMR (400 MHz, CDCl3) δ 8.79-8.18 (d, J = 2.4 Hz, 1H), 8.49-8.46 (m, 1H), 
7.75-7.73 (d, J = 8.8 Hz, 1H), 7.66 (s, 2H), 3.23-3.22 9 (m, 2H), 2.92-2.88 (t, J = 7.6 Hz, 2H). 
HRMS (ESI) m/z: calcd for C16H11Cl3N3O3 [M+H]+ 397.98, found 398.0. 
4-chloro-6-nitro-2-(2,4,6-trichlorophenethyl)quinazoline (21c).  Compound 21c (560 mg, 
48% yield) was prepared by the same method as 6d. HRMS (ESI) m/z: calcd for C16H10Cl4N3O2 
[M+H]+ 415.94, found 415.9. 
N1,N1-diethyl-N4-(6-nitro-2-(2,4,6-trichlorophenethyl)quinazolin-4-yl)pentane-1,4-diamine 
(21d).  Compound 21d (90 mg, 48% yield) was prepared by the same method as 6e.  HRMS 
(ESI) m/z: calcd for C25H31Cl3N5O2 [M+H]+ 538.14, found 538.1. 
  
N4-(5-(diethylamino)pentan-2-yl)-2-(2,4,6-trichlorophenethyl)quinazoline-4,6-diamine 
(21).  Compound 21 (90 mg, 48% yield) was prepared by the same method as 6. 1H NMR (400 
MHz, CDCl3) δ 8.70 (s,1H), 7.62-7.60 (d, J = 8.8 Hz, 1H), 7.30 (s, 2H) 7.26-7.24 (d, 2H), 7.12-
7.09 (d, J = 9.2 Hz, 1H), 6.35 (br, 1H), 4.44 (m, 1H), 3.46-3.04 (m, 2H), 2.94- 2.90 (m, 5H), 2.82-
2.80 (m, 1H), 1.31-1.29 (d, J = 6.4 Hz, 3H), 1.22-1.18 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, 
CDCl3): δ 168.9, 161.9, 158.4, 144.5, 142.7, 136.9, 136.0, 132.1, 128.0, 128.0, 123.1, 114.4, 
103.2, 51.9, 46.3, 37.1, 33.3, 29.8, 21.6, 20.8, 9.0. HRMS (ESI) m/z: calcd for C25H33Cl3N5+ 
[M+H]+ 508.17,  found 508.1. 
(E)-6-nitro-2-(4-(trifluoromethyl)styryl)quinazolin-4(3H)-one (22a). Compound 22a (170 
mg, 47% yield) was prepared by the same method as 6c. HRMS (ESI) m/z: calcd for 
C17H11F3N3O3 [M+H]+ 362.07, found 362.1. 
(E)-4-chloro-6-nitro-2-(4-(trifluoromethyl)styryl)quinazoline (22b).  Compound 22b (116 
mg, 65% yield) was prepared by the same method as 6d. HRMS (ESI) m/z: calcd for 
C17H10ClF3N3O2 [M+H]+ 380.03, found 380.0. 
(E)-N1,N1-diethyl-N4-(6-nitro-2-(4-(trifluoromethyl)styryl)quinazolin-4-yl)pentane-1,4-
diamine (22c).  Compound 22c (crude 100 mg) was prepared by the same method as 6e.The 
crude product was used in next step without further purification.  HRMS (ESI) m/z: calcd for 
C26H31F3N5O2 [M+H]+ 502.24, found 502.2. 
(E)-N4-(5-(diethylamino)pentan-2-yl)-2-(4-(trifluoromethyl)styryl)quinazoline-4,6-diamine 
(22). Compound 22 (70 mg, 75% yield) was prepared by the same method as 6.1H NMR (400 
MHz, CDCl3) δ 8.26 (s, 1H), 7.90-7.86 (d, J = 16.0 Hz, 1H), 7.71-7.60 (m, 5H), 7.39 (m, 1H) 
7.32-7.28 (m, 1H), 7.13-7.10 (m, 1H), 6.75-6.74 (d, J = 5.6 Hz, 1H), 4.68 (m, 1H), 3.05-2.99 (m, 
5H), 2.976-2.91 (m, 1H), 1.98-1.82 (m, 4H), 1.40-1.38 (d, J = 6.4 Hz, 3H), 1.25-1.21 (t, J = 7.2 
Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 168.4, 158.1, 156.7, 145.3, 142.4, 140.3, 133.9,131.2, 
130.0, 128.4, 127.4, 125.6, 125.6, 123.1, 115.3, 103.7, 51.7, 46.3, 46.2, 32.9, 21.2, 21.0, 8.3. 
HRMS (ESI) m/z: calcd for C26H33F3N5 [M+H]+ 472.26, found 472.3.   
(E)-6-nitro-2-(3-(trifluoromethyl)styryl)quinazolin-4(3H)-one (23a).  Compound 23a (286 
mg, 40% yield) was prepared by the same method as 6c. 1H NMR (400 MHz, DMSO-d6) δ 
12.79 (s, 1H), 8.81 (d, J = 2.4 Hz, 1H), 8.56-8.53 (m, 1H), 8.16-8.12 (d, J = 16.4 Hz, 1H), 8.045-
8.00 (m, 2H), 7.86-7.82 (m, 2H), 7.74-7.71 (t, J = 7.6 Hz, 1H), 7.21-7.17 (d, J = 16.0 Hz, 1H). 
HRMS (ESI) m/z: calcd for C17H11F3N3O3 [M+H]+ 362.07, found 362.1. 
  
(E)-4-chloro-6-nitro-2-(3-(trifluoromethyl)styryl)quinazoline (23b).  Compound 23b (210 
mg, 70% yield) was prepared by the same method as 6d. HRMS (ESI) m/z: calcd for 
C17H10ClF3N3O2 [M+H]+ 380.03, found 380.0. 
(E)-N1,N1-diethyl-N4-(6-nitro-2-(3-(trifluoromethyl)styryl)quinazolin-4-yl)pentane-1,4-
diamine (23c).  Compound 23c (132 mg, 48% yield) was prepared by the same method as 6e. 
HRMS (ESI) m/z: calcd for C26H31F3N5O2 [M+H]+ 502.24, found 502.2. 
(E)-N4-(5-(diethylamino)pentan-2-yl)-2-(3-(trifluoromethyl)styryl)quinazoline-4,6-diamine 
(23).  Compound 23 (68 mg, 54% yield) was prepared by the same method as 6.  1H NMR (400 
MHz, CDCl3) δ 8.67 (s, 1H), 7.90-7.86 (d, J =15.6 Hz, 1H), 7.81(m, 2H), 7.68-7.65 (d, J = 8.8 
Hz, 1H), 7.54-7,49 (m, 1H), 7.41-7,07 (m, 1H), 7.32-7.28 (d, J =15.6 Hz, 1H), 7.12-7.09 (m, 1H), 
6.79 (br, 1H), 4.69 (m, 1H), 3.07-3.00 (m, 5H), 2.97-2.92 (m, 1H), 2.00-1.90 (m, 4H), 1.40-1.39 
(d, J =6.8 Hz, 3H), 1.25-1.22 (t, J = 7.2 Hz, 6H);13C NMR (100 MHz, CDCl3) δ 168.8, 158.1, 
156.3, 145.7, 141.6, 137.5, 134.1, 131.2, 130.9, 130.0, 129.2, 127.8, 125.4, 124.8, 124.3, 124.2, 
123.2, 122.7, 115.2, 103.6, 51.7, 46.3, 46.1, 33.0, 21.2, 20.9, 8.4. HRMS (ESI) m/z: calcd for 
C26H33F3N5  [M+H]+ 472.26, found 472.2.   
(E)-6-nitro-2-(2-(trifluoromethyl)styryl)quinazolin-4(3H)-one (24a).  Compound 24a (306 
mg, 42% yield) was prepared by the same method as 6c. 1H NMR (400 MHz, DMSO-d6) δ 
12.99 (s, 1H), 8.81 (d, J = 2.8 Hz, 1H), 8.55-8.52 (m, 1H), 8.34-8.31 (d, J = 14.0 Hz, 1H), 7.96-
7.95 (d, J = 8.0 Hz, 1H), 7.90-7.80 (m, 3H, 7.69-7.65 (t, J = 7.6 Hz,1H), 7.11-7.07 (d, J = 15.6 
Hz, 1H). HRMS (ESI) m/z: calcd for C17H11F3N3O3 [M+H]+ 362.07, found 362.1. 
(E)-4-chloro-6-nitro-2-(2-(trifluoromethyl)styryl)quinazoline (24b).  Compound 24b (80 
mg, 64% yield) was prepared by the same method as 6d. HRMS (ESI) m/z: calcd for 
C17H10ClF3N3O2  [M+H]+ 380.03, found 380.0. 
(E)-N1,N1-diethyl-N4-(6-nitro-2-(2-(trifluoromethyl)styryl)quinazolin-4-yl)pentane-1,4-
diamine (24c).  Compound 24c (80 mg, 57% yield) was prepared by the same method as 6e.  
HRMS (ESI) m/z: calcd for C26H31F3N5O2  [M+H]+ 502.24, found 502.2. 
(E)-N4-(5-(diethylamino)pentan-2-yl)-2-(2-(trifluoromethyl)styryl)quinazoline-4,6-diamine 
(24).  Compound 24 (20 mg, 36% yield) was prepared by the same method as 6. 1H NMR (400 
MHz, CDCl3) δ 8.69 (s, 1H), 8.39-8.35 (m, 1H), 7.93-7.91 (d, J = 8.0 Hz, 1H), 7.69-7.64 (m, 2H), 
7.58-7.54 (t, J = 7.6 Hz, 1H), 7.40-7.36 (t, J = 7.6 Hz, 1H), 7.23-7.18 (d, J = 15.6 Hz, 1H), 7.13-
7.10 (m, 1H), 6.42 (br, 1H), 4.61 (m, 1H), 3.00-2.94 (m, 4H), 2.88-2.86 (m, 1H), 1.95-1.90 (m, 
  
4H), 1.41-1.39 (d, J = 6.4 Hz, 3H), 1.22-1.19 (t, J = 7.2 Hz, 6H);13C NMR (100 MHz, CDCl3) δ 
157.8, 157.0, 145.1, 135.7, 132.5, 132.0, 131.0, 128.9, 127.7, 127.2, 126.0, 123.0, 15.4, 103.5, 
51.7, 46.5, 46.1, 33.0, 21.3, 20.7, 8.5. HRMS (ESI) m/z: calcd for C26H33F3N5  [M+H]+ 472.26, 
found 472.2. 
RESULTS 
 Compounds Inhibit Protein Kinases.  Previously, structure-based virtual screening 
against CaMKIIδ led to 1 (Scheme 1), which inhibited the enzyme with single-digit micromolar 
IC50.  Kinome profiling against 337 kinases of 5 (an analog of 1 with identical IC50) revealed that 
CaMKIIδ was among the top 10 targets of the compound.  Also, the compound inhibited other 
members of CaMK family of proteins that included CaMKI and the maternal embryonic zipper 
kinase (MELK).  To better understand how these compounds engage the ATP-binding pocket of 
kinases, we selected MELK to pursue a limited structure-activity study.   
  
 
 Scheme 1.   Chemical structure of active compounds identified from virtual screening. 
  
 We purchased additional analogs of 1 (compounds 2-15) and tested several compounds 
for inhibition of MELK (Fig. 1a).  Compound 6 showed the most potent activity with more than 
98% inhibition at 20 µM.  To identify additional targets for 6, we tested whether the compound 
inhibited the activity of the top 25 kinase targets of compound 1 that were identified from a 
previous profiling of 337 kinases (Fig. 1b).  We found that 6 inhibits kinases with IC50 values 
ranging from 1.4 ± 0.9 µM for MELK to 42.7 ± 4.6 µM for FER kinase.  Compound 6 inhibited 
  
two other kinases with an IC50 less than 2 µM, namely BMX/ETK (1.9 ± 0.6 µM) and TIE2/TEK 
(1.8 ± 0.9 µM). 
 To explore the role of each substituent of 6 on the inhibition of MELK activity, we 
prepared 9 derivatives of the compound (Scheme 2, Scheme 3, and Fig. 1c).  The role of the 
amine at R2 was investigated by replacing it with a methoxy group affording compound 16.  The 
compound was three-fold weaker than 6 suggesting that the amino group was engaged in 
favorable interactions likely through hydrogen bonding (Fig. 1d).  The role of the R1 group was 
explored in compounds 17, 18, and 19.  In 17 and 19 the N-alkylmine moiety was shortened 
resulting in two-fold increase in the IC50 over the parental compound.  Removal of the methyl 
group at the carbon atom directly attached to the quinazoline ring in 18 led to little effect on the 
IC50.  An introduction of a morpholino group in 20 led to a two-fold reduction in activity. The 
effect of the olefin at R3 was explored by the synthesis of 21.  The loss of activity by nearly 3-
fold suggests that a planar moiety at R1 is preferable for optimal binding to the kinase.  This 
group interacts with sidechains of the hinge loop in the ATP-binding pocket of the enzyme (Fig. 
1d).  At R3, a trifluoromethyl moiety was introduced at the para (compound 22), meta 
(compound 23), ortho (compound 24) positions of the ring.  Both 23 and 24 had 3-fold weaker 
activity than the parent compound, except for 22, which resulted in a similar IC50. 
 
Scheme 2.     Synthesis of derivatives of 6 (KIN-281). 
 
  
 
Scheme 3. Synthesis of 21. 
 Compounds Inhibit Cancer Cell Growth in Anchorage-Dependent and Independent 
Assays. Considering that the kinases inhibited by the compound are known to be up-regulated 
in various basal-like breast tumors, we explored the effect of 1-15 on breast MDA-MB-231 cell 
viability (Fig. 2). Most of the compounds inhibited breast MDA-MB-231 cell growth with IC50 
values that ranged from 2 to 30 µM (Fig. 2a). Except for 15 (KIN-288) and 12 (KIN-289), all 
compounds had IC50 values that were lower than 10 µM. The most potent compound was 6 
(KIN-281) with an IC50 of 2 µM.  We also explored the effect of the compounds in anchorage-
independent growth assay in soft agar. Colony formation in soft agar provides a better 
representation of oncogenic transformation, tumor growth, as well the potential for tumors to 
metastasize 2.  MDA-MB-231 cells form colonies in soft agar as illustrated in Fig. 2b and 2c. 
Compounds 1 (KIN-1), 5 (KIN-236), 6 (KIN-281) and 7 (KIN-283) inhibited colony formation in a 
concentration-dependent manner with IC50 values ranging from 3 to 7 µM. Consistent with cell 
viability studies, 6 (KIN-281) was generally more potent than the other three compounds. 
  
 
Figure 1. Small molecules inhibit MELK kinase. (a) Derivatives of 1 (KIN-1) were tested for 
inhibition of MELK activity at 20 µM; data shown as mean ±SD. (b) Compound 6 
(KIN-281) was tested for its inhibition of 25 kinases that were selected from a 
previous kinome profiling.  IC50s were obtained for each kinase; data shown as mean 
±SD.  (c) Chemical structure of derivatives of 6 (KIN-281) that were synthesized 
along with IC50 for inhibition of MELK activity. (d) Predicted binding mode of 6 (KIN-
281) to MELK ATP pocket.  
 
 
 
 
Figure 2.  Compounds inhibits anchorage dependent 
and independent growth.  (a)  Effect of 1 (KIN-1) and derivatives on MDA-MB-231 
measured by MTT over 3 days; data are shown as mean ±SD (n = 3) (b) Inhibition of 
anchorage-independent growth in MDA-MB-231 cancer cells (c) Quantification of 
  
data in (b); each value represents the mean ± SE taken from six diﬀerent fields from 
two independent samples. 
  Compounds Up-regulate p21WAF1/CIP1 in a p53-dependent Manner.  Previous studies 
had shown that MELK contributes to cell cycle progression by causing G/M arrest 3, 4, and 
reduced the number of cells at the G2/M transition 4, 5. These studies also showed that 
knockdown of MELK resulted in up-regulation of p21WAF1/CIP1 in U87 GBM cell lines 4. We 
observed the same effect for 1 (KIN-1) and 6 (KIN-281); at 5 µM, the compound up-regulated 
p21WAF1/CIP1 in MDA-MB-468 (Fig. 3a and 3b) and MDA-MB-231 (Fig. 3c and 3d).  A time-
dependent study was conducted with both of these cell lines.  After 4 h, both 1 (KIN-1) and 6 
(KIN-281) up-regulate p21WAF1/CIP1. The effect on p21WAF1/CIP1 was sustained over 48 h in both 
cell lines.  We investigated the effects of p21WAF1/CIP1 on cyclins, which are inhibitors of 
p21WAF1/CIP1.  We found that an increase in p21WAF1/CIP1 corresponded closely to a decrease in 
cyclin A2, which was gradually down-regulated over the course of 48 h (Fig. 3a to 3d). 
         Although p21WAF1/CIP1 is a p53 target gene, treatment of MDA-MB-468 cells with 1 (KIN-1) 
and 6 (KIN-281) showed no effect on p53 levels over 48 h (Fig. 3e).   We investigated whether 
the compounds had any effects on p53 phosphorylation, particularly at Ser15, which has been 
previously found to be affected by MELK suppression. Phosphorylation at Ser15 inhibits the 
interaction of p53 with its antagonists MDM2 or MDMX, which de-stabilize p53 and inhibit 
apoptosis.  Interestingly, both compounds inhibited phosphorylation at Ser15 of p53 consistent 
with a potential effect on MELK activity (Fig. 3f). 
  
 
Figure 3.  Compounds up-regulate p21.  (a) Detection of cyclin A2 and p21 levels over the 
course of 48 h as a result of treatment MDA-MB-468 cells. β-actin serves as loading 
control. (b) Quantification of data shown in (a).  The data are presented as 
percentage changes (mean ± SD; n = 2).  (c)  Detection of cyclin A2 and p21 levels 
in MDA-MB-231 cells following treatment with 1 (KIN-1) and 6 (KIN-281) over 48 h.  
Actin is used as loading control. (d) Quantification of data in (c); the data are 
presented as percentage changes relative to control (mean ± SD; n = 2). (e) 
Detection of p53 phosphorylation and p53 levels following treatment of MDA-MB-468 
cells over 48 h.  Actin is used as loading control. (f) Effect of increasing 
concentration of KIN-281 on MDMX levels detected by immunoblot analysis following 
treatment of MDA-MB-231.  
 Compounds Block STAT3 and Down-regulate Pro-Apoptotic Markers Survivin and 
Bcl-XL. Both 1 (KIN-1) and 6 (KIN-281) inhibited STAT3 phosphorylation in MDA-MB-468 (Fig. 
4a and 4b) and MDA-MB-231 (Fig. 4c and 4d) cells.  A time course revealed that STAT3 
phosphorylation was completely inhibited at 4 h, but phosphorylation levels were restored after 
8 h in MDA-MB-468 cells.  A similar observation was made in MDA-MB-231 except that these 
cells recover STAT3 phosphorylation levels more slowly.  The effect on STAT3 phosphorylation 
was confirmed with electrophoresis mobility shift assay (EMSA), which showed that 1 (KIN-1) 
  
inhibited STAT3 dimer binding to DNA (Fig. 4e).  It is of interest to note that JAK kinase activity 
was not affected by our compounds as evidenced by the lack of inhibition of JAK kinase activity 
by 6 (Fig. 4f).  This suggests that the inhibitors are following a non-canonical pathway to 
blocking STAT3.  Previous studies have suggested that BMX promotes STAT3 activation 
through the PI3K pathway in a manner that is independent of Akt 6.  We find that 1 (KIN-1) or 6 
(KIN-281) had no effect on Akt phosphorylation (Fig. 4g and 4h). 
          It is often the case that STAT3 phosphorylation leads to down-regulation of survivin 7, 8.  
Survivin is a member of the XIAP (X-linked inhibitor of apoptosis) group of proteins.  Studies 
have shown that survivin works in a complex mechanism to promote cell growth and to inhibit 
apoptosis.  Survivin is a component of the chromosomal passenger complex (CPC) and hence 
has a critical role cell cycle progression and cell proliferation 9, 10 11, 12. Interestingly, 1 (KIN-1) 
and 6 (KIN-281) led to down-regulation of survivin in MDA-MB-468 (Fig. 4a and 4b) and MDA-
MB-231 (Fig. 4c and 4d). The effect was sustained over the course of 48 h in both MDA-MB-
468 and MDA-MB-231.  Interestingly, both 1 and 6 also reduced expression of the pro-apoptotic 
protein Bcl-XL (Fig. 4a-d). 
 
Figure 4.  Compounds Impair STAT3 phosphorylation and Down-regulate Pro-apoptotic Bcl-XL and Survivin.  
(a)  Effect of 1 (KIN-1) and 6 (KIN-281) on STAT3, Bcl-XL, and survivin levels as well as STAT3 phosphorylation 
analyzed by Western blot analysis at several time intervals over the course of 48 h in MDA-MB-468 cells. β-actin is 
  
used as loading control.  (b) Quantification of data in (a); the data are presented as percentage changes relative to 
control (mean ± SD; n = 2). (c)  Effect of 1 (KIN-1) and 6 (KIN-281) on STAT3, Bcl-XL, and survivin levels as well as 
STAT3 phosphorylation analyzed by Western blot analysis at several time intervals over the course of 48 h in MDA-
MB-231 cells. β-actin is used as loading control.  (d) Quantification of data in (a); the data are presented as 
percentage changes relative to control (mean ± SD; n = 2).  (e) EMSA analysis to establish STAT3 binding to DNA; 
lane 1 is  (f) Activity of 6 against JAK1, JAK2 and JAK3 kinases. (g)  Western blot analysis of Akt phosphorylation as 
a result of treatment with 1.  (h) Quantification of data in (g); the data are presented as percentage changes relative 
to control (mean ± SD; n = 2).   
  KIN-281 Inhibits Cell Autophagy. A direct physical interaction between the anti-
apoptotic proteins Bcl-2 or Bcl-XL and the autophagy regulator Beclin-1 was previously shown 
to inhibit autophagy in cancer cells 13.  In addition, it has been shown that STAT3 promotes 
autophagy through a complex with PKR 14.  Since 1 and 6 suppress Bcl-XL levels and inhibit 
STAT3 activation, we wondered whether treatment with these compounds had an effect on 
autophagic flux. To test this, levels of the processed LC3B, a widely used marker of autophagy 
15
 were measured in MDA-MB-231 and MDA-MB-468 cells following treatment with compound. 
Autophagic flux was evaluated by determining the levels of LC3B-I and LC3B-II by Western blot 
analysis in the presence or absence of the lysosomotropic agent bafilomycin A1 (BafA1) that 
inhibits autophagy at late stages. In both cases, we found that the compounds led to increased 
levels of LC3B-II (Fig. 5).  Treatment of MDA-MB-468 cells with BafA1 resulted in substantial 
increase in LC3B-II compared to DMSO control consistent with there being robust autophagic 
flux in these cells at basal conditions. MDA-MB-231 cells showed a more modest increase in 
LC3B-II when treated with BafA1. Growth of cells at 1% oxygen (hypoxia) was used as a 
positive control for autophagy induction (lanes 5 and 6 in Fig. 5a and Fig. 5b). A pronounced 
increase in LC3B-II levels were detected in MDA-B-468 cells (lane 3 in Fig. 5a) and MDA-MB-
231 cells (lane 3 in Fig. 5b) treated with compound.  However, this was not further increased by 
co-treatment with BafA1 in either MDA-MB-468 or MDA-MB-231 cells suggesting that the 
compound was inhibiting autophagic flux and causing processed LC3B-II to accumulate. 
 
 
 
 
  
Figure 5.    Compounds Inhibit Cell Autophagy.  Compounds inhibit autophagy.  Western blot analysis of LC3B-I 
and LC3B-II in MDA-MB-468 cells (a) and MDA-MB-231 cells (b) following treatment for 4 h in vehicle control 
(DMSO), 5 µM 6 (KIN-281) or at 1% oxygen. Bafilomycin A1 was added at 100 nM for the last 4 hours of incubation 
to lanes 2, 4 and 6 as indicated. 
DISCUSSION 
 Here we test previously-identified quinazoline compounds in TNBC breast cancer cells 
and found them to inhibit cell viability and to impair colony formation in an anchorage-
independent soft agar assay.  The most potent among these compounds, namely 6 (KIN-281), 
inhibits several kinases with IC50s of approximately 1 µM, including maternal embryonic leucine 
zipper kinase (MELK), bone marrow X-linked (BMX). Studies have shown that both MELK and 
BMX are overexpressed in a number of tumors and their overexpression correlates strongly with 
patient outcome 16-18.  BMX is a member of the Tec non-receptor tyrosine kinase family.  MELK 
has been identified as an important target for other epithelial tumors including colorectal, lung, 
breast, ovarian and brain 19. High expression of MELK in cancer stem cells has also been found 
20, 21
.  MELK is overexpressed in basal-like breast cancer and several studies have implicated 
the enzyme with tumor growth and metastasis 4, 22.  The inhibition of MELK, BMX and other 
kinases by 6 may explain its effect in TNBC cancer cells. 
Some of the effects that we observed for 6 (KIN-281) may be partly associated with 
inhibition of MELK or BMX. MELK plays an important role in cell cycle 23-26.  Previous studies 
have shown that knockdown of MELK in U87 led to p21WAF1/CIP1 up-regulation 4. Interestingly, we 
found that our compounds up-regulated p21WAF1/CIP1 in a time-dependent manner over 48 h. The 
down-regulation of cyclin A2 that is induced by the compounds is consistent with the effect on 
p21WAF1/CIP1.  Studies that have suggested that the effect on p21WAF1/CIP1 is a p53-dependent 
process have been conflicting.  One study has shown that MELK suppression has no effect on 
Ser15 phosphorylation in U87 or levels of p53, suggesting instead that the effect on p53 may be 
due to MDMX down-regulation rather than an effect on p53 4. Another study found that 
suppressing MELK led to inhibition of Ser15 phosphorylation and increased stabilization of p53 
27
. 1 (KIN-1) and 6 (KIN-281) had no effect on the levels of p53 in agreement with both studies. 
However, the compound inhibited Ser15 phosphorylation in a time-dependent fashion consistent 
with the results of Seong and co-workers 27.  We investigated the effect of the compounds on 
MDMX levels and observed an increase in MDMX, consistent with the observation of Seong and 
co-workers with MDM2 27. 6 (KIN-281) does not affect p53 levels in MDA-MB-468 or MDA-MB-
231 cells.  
  
BMX is an intracellular non-receptor tyrosine kinase member of the Tec family of protein 
kinases.  Like other Tec kinases, BMX possesses a membrane localization pleckstrin homology 
(PH) module along with a BH, SH3, SH2, and kinase domains that mediate protein-protein 
interactions and downstream signaling. BMX has been shown to directly associate and 
phosphorylate STAT3 28.  This process was found to be independent of JAK kinases, which are 
generally associated with STAT3 activation 29.  The inhibition BMX by 6 prompted us to explore 
whether STAT3 phosphorylation is affected in both MDA-MB-231 and MDA-MB-468.  STAT 
proteins have dual roles: they transduce signals through the cytoplasm and function as 
transcription factors in the nucleus 30, 31. Following phosphorylation from specific tyrosine 
kinases, STATs form stable homodimers, sometimes heterodimers, through SRC homology 2 
(SH2) domain interactions.  In the nucleus, a STAT3 dimer complex bind to DNA and modulate 
the transcription of genes that play a critical role in promoting inflammatory and malignant 
processes.  The effects on STAT3 went beyond merely inhibition of phosphorylation of the 
transcription factor.  We found through EMSA that 1 (KIN-1) inhibited STAT3 DNA-binding. This 
suggests that the compound is likely also affecting STAT3 transcription factor activity. However, 
compound 6 had no effect on JAK kinases suggesting that inhibition of STAT3 occurs through 
another mechanism, possibly through PI3K by activation of BMX.  A recent study has shown 
that phosphorylation of STAT3 in PI3K-transformed cells is driven by BMX 6. The study 
demonstrates that instead of the usual PIP3/Akt/mTOR pathway, PIP3 leads to phosphorylation 
of BMX, which in turn phosphorylates STAT3 and leads to oncogenic phenotype (Fig. 6). In fact, 
we tested the effects of the compounds on Akt phosphorylation and found no effect confirming 
that the compound does not affect the PI3K/Akt/mTOR pathway. 
We found that the compounds also suppressed the levels of pro-apoptotic survivin and 
Bcl-XL. Although survivin is often associated with apoptosis, it is a cell cycle protein that is 
highly up-regulated in cancer versus normal cells. Survivin has multiple functions.  Initially 
thought to be strictly involved in programmed cell death, survivin has been shown to play a key 
role in cell cycle progression and cell proliferation.  In fact, survivin is required for several stages 
of cell division.  At metaphase, it localizes to kinetochores then transfers to the central spindle 
mid-zone at anaphase, and finally accumulates in mid-bodies at telophase 32.  It physically 
associates with polymerized microtubules, mitotic chromatin-associated spindle microtubules, 
and the kinetochore-associated CPC through protein-protein interactions with Aurora B 9, 10, 
Borealin/Dasra B 11, and Crm1 12.  Expression of survivin is controlled by several transcription 
factors including p53, FoxM1, and STAT3.  
  
 The effects of 6 on STAT3 levels and Bcl-XL prompted us to explore the effect of the 
compounds on cell autophagy.  Bcl-XL forms a physical interaction with the BH3 domain of 
beclin-1 33. Phosphorylation of beclin-1 by the CaMK member death-associated protein kinase 1 
(DAPK1) leads to the disruption of the Bcl-XL•beclin-1 complex and subsequent increase in 
autophagy 34. Previous studies have shown that STAT3 promotes autophagy through a complex 
with PKR (Fig. 6) 14.  Autophagy is a highly conserved self-degradative process that plays a 
critical role in cellular stress response and survival mechanisms.  Cells use autophagy to 
turnover damaged organelles, pathogens and large protein aggregates.  This degradation 
process provides a critical source of amino acids, nucleotides, and fatty acids, especially for 
cancer cells, which are generally unable to acquire sufficient nutrients to sustain the ATP 
production required for these cells to survive. A commonly used marker for autophagy is LC3B-
II 15.  We found that 6 (KIN-281) led to a significant increase in LC3-II levels suggesting that 
MELK may play a role in suppressing autophagy.  The effects of the compound at 5 µM were as 
pronounced as bafilomycin A1, a well-known late-stage autophagy inhibitor. Inhibition of 
autophagy may have benefits for cancer treatment, particularly breast cancer where autophagy 
may help cells evade apoptosis 35, 36.  Beyond cell survival, accumulating evidence suggests 
that autophagy is involved in nearly every step of the metastatic cascade.  In fact, 50% of 
human breast cancers exhibit heterozygous deletion of beclin-1, which is critical for 
autophagosome formation 37, 38. By inhibiting autophagy, these compounds may thus have a 
beneficial effect for TNBC patients by limiting progression of disease. 
 
  
 
Figure 6.  Schematic illustrating potential mechanism of action of KIN-281.  Inhibition of BMX by the compound 
may be responsible for suppressing STAT3 activation through the PI3K pathway without affecting AKT.  STAT3 
activation leads to eIF2A phosphorylation and autophagy. 
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